Logo image of HALO

HALOZYME THERAPEUTICS INC (HALO) Stock Fundamental Analysis

NASDAQ:HALO - Nasdaq - US40637H1095 - Common Stock - Currency: USD

58.66  +1.12 (+1.95%)

Fundamental Rating

8

Overall HALO gets a fundamental rating of 8 out of 10. We evaluated HALO against 556 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is growing strongly while it also seems undervalued. This is an interesting combination This makes HALO very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

HALO had positive earnings in the past year.
In the past year HALO had a positive cash flow from operations.
Each year in the past 5 years HALO has been profitable.
Each year in the past 5 years HALO had a positive operating cash flow.
HALO Yearly Net Income VS EBIT VS OCF VS FCFHALO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

1.2 Ratios

HALO's Return On Assets of 22.10% is amongst the best of the industry. HALO outperforms 98.02% of its industry peers.
With an excellent Return On Equity value of 100.64%, HALO belongs to the best of the industry, outperforming 99.28% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 23.44%, HALO belongs to the top of the industry, outperforming 98.20% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for HALO is above the industry average of 14.97%.
The 3 year average ROIC (17.81%) for HALO is below the current ROIC(23.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 22.1%
ROE 100.64%
ROIC 23.44%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
HALO Yearly ROA, ROE, ROICHALO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 200 300

1.3 Margins

HALO's Profit Margin of 44.76% is amongst the best of the industry. HALO outperforms 98.74% of its industry peers.
HALO's Profit Margin has declined in the last couple of years.
HALO has a Operating Margin of 55.10%. This is amongst the best in the industry. HALO outperforms 100.00% of its industry peers.
In the last couple of years the Operating Margin of HALO has declined.
The Gross Margin of HALO (83.45%) is better than 87.41% of its industry peers.
HALO's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 55.1%
PM (TTM) 44.76%
GM 83.45%
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
HALO Yearly Profit, Operating, Gross MarginsHALO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

8

2. Health

2.1 Basic Checks

HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
HALO has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, HALO has less shares outstanding
The debt/assets ratio for HALO has been reduced compared to a year ago.
HALO Yearly Shares OutstandingHALO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
HALO Yearly Total Debt VS Total AssetsHALO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

An Altman-Z score of 4.78 indicates that HALO is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 4.78, HALO is doing good in the industry, outperforming 76.62% of the companies in the same industry.
The Debt to FCF ratio of HALO is 3.04, which is a good value as it means it would take HALO, 3.04 years of fcf income to pay off all of its debts.
HALO has a Debt to FCF ratio of 3.04. This is amongst the best in the industry. HALO outperforms 93.88% of its industry peers.
HALO has a Debt/Equity ratio of 3.13. This is a high value indicating a heavy dependency on external financing.
HALO has a Debt to Equity ratio of 3.13. This is amonst the worse of the industry: HALO underperforms 82.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.13
Debt/FCF 3.04
Altman-Z 4.78
ROIC/WACC2.65
WACC8.86%
HALO Yearly LT Debt VS Equity VS FCFHALO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

HALO has a Current Ratio of 8.39. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of HALO (8.39) is better than 71.76% of its industry peers.
HALO has a Quick Ratio of 7.30. This indicates that HALO is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 7.30, HALO is doing good in the industry, outperforming 67.45% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.39
Quick Ratio 7.3
HALO Yearly Current Assets VS Current LiabilitesHALO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.77% over the past year.
Measured over the past years, HALO shows a very strong growth in Earnings Per Share. The EPS has been growing by 30.12% on average per year.
Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 25.66%.
The Revenue has been growing by 38.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.77%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%40.51%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%35.22%

3.2 Future

Based on estimates for the next years, HALO will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.77% on average per year.
HALO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.63% yearly.
EPS Next Y32.62%
EPS Next 2Y34.39%
EPS Next 3Y30.64%
EPS Next 5Y16.77%
Revenue Next Year24.54%
Revenue Next 2Y22.13%
Revenue Next 3Y19.67%
Revenue Next 5Y12.63%

3.3 Evolution

The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
HALO Yearly Revenue VS EstimatesHALO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
HALO Yearly EPS VS EstimatesHALO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4 6 8 10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

HALO is valuated correctly with a Price/Earnings ratio of 12.89.
Based on the Price/Earnings ratio, HALO is valued cheaply inside the industry as 96.58% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.53, HALO is valued rather cheaply.
HALO is valuated cheaply with a Price/Forward Earnings ratio of 7.68.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HALO indicates a rather cheap valuation: HALO is cheaper than 98.20% of the companies listed in the same industry.
HALO's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 36.71.
Industry RankSector Rank
PE 12.89
Fwd PE 7.68
HALO Price Earnings VS Forward Price EarningsHALO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

96.94% of the companies in the same industry are more expensive than HALO, based on the Enterprise Value to EBITDA ratio.
HALO's Price/Free Cash Flow ratio is rather cheap when compared to the industry. HALO is cheaper than 95.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF 14.58
EV/EBITDA 10.72
HALO Per share dataHALO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of HALO may justify a higher PE ratio.
HALO's earnings are expected to grow with 30.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y34.39%
EPS Next 3Y30.64%

More info and screens

0

5. Dividend

5.1 Amount

HALO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HALOZYME THERAPEUTICS INC

NASDAQ:HALO (7/23/2025, 3:30:03 PM)

58.66

+1.12 (+1.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners101.72%
Inst Owner Change-0.53%
Ins Owners0.82%
Ins Owner Change1.05%
Market Cap7.23B
Analysts74.67
Price Target67.96 (15.85%)
Short Float %8.35%
Short Ratio3.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.72%
Min EPS beat(2)6.64%
Max EPS beat(2)14.79%
EPS beat(4)4
Avg EPS beat(4)16.48%
Min EPS beat(4)6.64%
Max EPS beat(4)26.79%
EPS beat(8)7
Avg EPS beat(8)11.76%
EPS beat(12)10
Avg EPS beat(12)11.39%
EPS beat(16)13
Avg EPS beat(16)12.38%
Revenue beat(2)2
Avg Revenue beat(2)7.09%
Min Revenue beat(2)1.36%
Max Revenue beat(2)12.81%
Revenue beat(4)4
Avg Revenue beat(4)9.53%
Min Revenue beat(4)1.36%
Max Revenue beat(4)13.28%
Revenue beat(8)5
Avg Revenue beat(8)4.78%
Revenue beat(12)7
Avg Revenue beat(12)3.03%
Revenue beat(16)9
Avg Revenue beat(16)3.86%
PT rev (1m)-5.59%
PT rev (3m)-1.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.89%
EPS NY rev (1m)0%
EPS NY rev (3m)6.28%
Revenue NQ rev (1m)1.47%
Revenue NQ rev (3m)2.21%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)4.51%
Valuation
Industry RankSector Rank
PE 12.89
Fwd PE 7.68
P/S 6.67
P/FCF 14.58
P/OCF 14.35
P/B 14.99
P/tB N/A
EV/EBITDA 10.72
EPS(TTM)4.55
EY7.76%
EPS(NY)7.64
Fwd EY13.02%
FCF(TTM)4.02
FCFY6.86%
OCF(TTM)4.09
OCFY6.97%
SpS8.8
BVpS3.91
TBVpS-2.59
PEG (NY)0.4
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 22.1%
ROE 100.64%
ROCE 29.2%
ROIC 23.44%
ROICexc 36.94%
ROICexgc 96.44%
OM 55.1%
PM (TTM) 44.76%
GM 83.45%
FCFM 45.72%
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexcg growth 3Y-1.13%
ROICexcg growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score9
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 3.13
Debt/FCF 3.04
Debt/EBITDA 2.22
Cap/Depr 9.93%
Cap/Sales 0.75%
Interest Coverage 250
Cash Conversion 74.2%
Profit Quality 102.14%
Current Ratio 8.39
Quick Ratio 7.3
Altman-Z 4.78
F-Score9
WACC8.86%
ROIC/WACC2.65
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)46.77%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%40.51%
EPS Next Y32.62%
EPS Next 2Y34.39%
EPS Next 3Y30.64%
EPS Next 5Y16.77%
Revenue 1Y (TTM)25.66%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%35.22%
Revenue Next Year24.54%
Revenue Next 2Y22.13%
Revenue Next 3Y19.67%
Revenue Next 5Y12.63%
EBIT growth 1Y56.46%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year50.06%
EBIT Next 3Y27.87%
EBIT Next 5Y15.57%
FCF growth 1Y88.07%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y80.4%
OCF growth 3Y16.96%
OCF growth 5YN/A